R-Pharm
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, R-Pharm sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
R-Pharm: 19 sponsored US clinical trials, none currently recruiting.
R-Pharm sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 3 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.
Top-decile sponsor footprint
R-Pharm ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
NCT00883116
Phase I Combination Ixabepilone + Cisplatin
NCT00832117
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
NCT00723957
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
NCT00634088
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
NCT00593827
Phase 1 Trial of Oral Ixabepilone
NCT00632424
Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer
NCT00546364
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
NCT00370552
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
NCT00383149
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
NCT00422097
Ixabepilone Administered as an Enteric Coated Formulation.
NCT00309049
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
NCT00207090
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
NCT00162136
Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
NCT00207129
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
NCT00080262
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
NCT00082433
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
NCT00080301
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy
NCT00035516
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
NCT00004927
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 7 |
| Phase 3 | 3 |
Therapeutic Areas
How the R-Pharm early-phase archive is shaped
19 indexed studies, none listed as recruiting (0% open); 15 completed (79%).
Phase mix: 3 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (2 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
R-Pharm: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
R-Pharm sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this R-Pharm page
19 registered trials is a research-attention snapshot, not an endorsement of R-Pharm or any single study.
- None of R-Pharm's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Breast Cancer is the condition R-Pharm studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
R-Pharm pipeline card: 19 registered trials from official public datasets.Report a data error.